Spotlight on the SAPIEN 3 transcatheter heart valve

Tobias Rheude,1 Johannes Blumenstein,2 Helge Möllmann,2 Oliver Husser2 1Department of Cardiovascular Diseases, German Heart Centre, Technical University Munich, Munich, Germany; 2Department of Cardiology, St.-Johannes-Hospital, Dortmund, Germany Abstract: Transcatheter aortic valve implanta...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rheude T, Blumenstein J, Möllmann H, Husser O
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://doaj.org/article/0d01def058da445ba41ef4f037e34a8a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Tobias Rheude,1 Johannes Blumenstein,2 Helge Möllmann,2 Oliver Husser2 1Department of Cardiovascular Diseases, German Heart Centre, Technical University Munich, Munich, Germany; 2Department of Cardiology, St.-Johannes-Hospital, Dortmund, Germany Abstract: Transcatheter aortic valve implantation (TAVI) is increasingly performed in patients with severe aortic stenosis. The efficacy and safety have been demonstrated in large randomized trials in patients with high- or intermediate operative risk. With latest-generation transcatheter heart valve (THV) systems, growing operator experience and improved patient selection, clinical outcome has significantly improved with a decline of TAVI-related complications. In this review, the Edwards SAPIEN 3 THV is discussed in terms of technology, procedural advances and complication trends and future developments. Keywords: aortic valve stenosis, transcatheter aortic valve implantation, TAVI, transcatheter heart valves, Edwards SAPIEN 3